Pharmacokinetic–pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice
详细信息 查看全文
- 作者：Ryosuke Shimizu ; Mikiko Kitade…
- 关键词：PK–PD model ; Antisense oligonucleotides ; Apolipoprotein B ; Time ; delay
- 刊名：Journal of Pharmacokinetics and Pharmacodynamics
- 出版年：2015
- 出版时间：February 2015
- 年：2015
- 卷：42
- 期：1
- 页码：67-77
- 全文大小：970 KB
- 参考文献：1. Yu RZ, Grundy JS, Geary RS (2013) Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol 9:169-82. doi:10.1517/17425255.2013.737320 CrossRef
2. Grünweller A, Hartmann RK (2007) Locked nucleic acid oligonucleotides: the next generation of antisense agents? BioDrugs 21:235-43 CrossRef
3. Kimber WL, Puri N, Borgmeyer C, Ritter D, Sharov A, Seidman M, Ko MS (2003) Efficacy of 2-methoxyethoxy-modified antisense oligonucleotides for the study of mouse preimplantation development. Reprod Biomed Online 6:318-22 CrossRef
4. Obika S, Rahman SM, Song B, Onoda M, Koizumi M, Morita K, Imanishi T (2008) Synthesis and properties of 3-amino-2-4-BNA, a bridged nucleic acid with a N3′?→?P5-phosphoramidate linkage. Bioorg Med Chem 16:9230-237. doi:10.1016/j.bmc.2008.09.013 CrossRef
5. Straarup EM, Fisker N, Hedtj?rn M, Lindholm MW, Rosenbohm C, Aarup V, Hansen HF, ?rum H, Hansen JB, Koch T (2010) Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 38:7100-111. doi:10.1093/nar/gkq457 CrossRef
6. Grünweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2- / O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31:3185-193 CrossRef
7. Geary RS (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5:381-91 CrossRef
8. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M (2013) Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 62:2178-184. doi:10.1016/j.jacc.2013.07.081 CrossRef
9. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E (2008) A phase I study of OGX-011, a 2-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14(3):833-39 CrossRef
10. Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, Wedel MK, Levin AA, Geary RS (2009) Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 77:910-19. doi:10.1016/j.bcp.2008.11.005 CrossRef
11. Yu RZ, Zhang H, Geary RS, Graham M, Masarjian L, Lemonidis K, Crooke R, Dean NM, Levin AA (2001) Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther 296:388-95
12. Callies S, André V, Patel B, Waters D, Francis P, Burgess M, Lahn M (2011) Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide. Br J Clin Pharmacol 71:416-28 CrossRef
13. Turnpenny P, Rawal J, Schardt T, Lamoratta S, Mueller H, Weber M, Brady K (2011) Quantitation of locked nucleic acid antisense oligonucleotides in mouse tissue using a liquid–liquid extraction LC–MS/MS analytical approach. Bioanalysis 3:1911-921. doi:10.4155/bio.11.100
文摘
Second-generation antisense oligonucleotides (ASOs) demonstrate excellent biological stability and in vitro/in vivo potency, and thus are considered to be attractive candidates for drugs to treat various diseases. A pharmacokinetic–pharmacodynamic (PK–PD) model of ASOs is desired for the design of appropriate PK and pharmacological studies. The objective of this study was to develop a PK–PD model to accurately simulate hepatic ASO concentration and its efficacy from plasma ASO concentration. After single subcutaneous administration of an ASO targeting hepatic apolipoprotein B (Apo-B) mRNA to mice, the ASO was absorbed rapidly and showed biphasic decline with time from the plasma and liver (t1/2: 1- and 81-83?h, Tmax: 0.25-.50 and 4-?h). After administration, hepatic Apo-B mRNA and plasma total cholesterol began decreasing at 4- and 8-4?h, and their Tmax values were observed at 24-2 and 72?h. To develop the PK–PD model based on the mechanisms of ASOs, we described the plasma and hepatic ASO concentration with linear two-compartment models. In addition, we inserted two indirect response models for mRNA and plasma total cholesterol. Model predictions from plasma ASO concentration gave excellent fits to the observed values of hepatic ASO concentration, Apo-B mRNA and plasma total cholesterol after single or multiple subcutaneous administrations. Our PK–PD model could accurately predict hepatic ASO concentrations and their efficacies from plasma ASO concentrations. This PK–PD model could be a useful tool for suggesting PK and pharmacological study protocols for various liver-targeted second-generation ASOs.